The National Health Service in England has set out what it says is its “final” offer to enable patients in England to access Vertex’s cystic fibrosis drugs, including Orkambi (lumacaftor/ivacaftor). The amount offered by NHS England would represent the biggest financial commitment in its history.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?